JXG: Shunt, Central Nervous System And Components

Product code JXG, “Shunt, Central Nervous System And Components” in FDA's classification database, is a Class II device type under 21 CFR 882.5550 (central nervous system fluid shunt and components), reviewed by FDA's Neurology panel. FDA's 510(k) database lists 260 clearances under JXG, 67 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
JXG
Regulation
21 CFR 882.5550
Class
II
Panel
Neurology
Clearances
260
Most recent
Oct 2, 2026
Median review, last 2 years
245 days
Third-party review
Not eligible
Implant
Yes

What it covers

A central nervous system fluid shunt is a device or combination of devices used to divert fluid from the brain or other part of the central nervous system to an internal delivery site or an external receptacle for the purpose of relieving elevated intracranial pressure or fluid volume (e.g., due to hydrocephalus). Components of a central nervous system shunt include catheters, valved catheters, valves, connectors, and other accessory components intended to facilitate use of the shunt or evaluation of a patient with a shunt.

The identification in 21 CFR 882.5550, central nervous system fluid shunt and components. FDA gives JXG no definition of its own, so the regulation’s describes it.

FDA flags JXG devices as implants.

Recent clearances

510(k)DeviceApplicantDecisionType
K260044Ventricular Catheters, Thomale CatheterAesculap, Inc.Oct 2, 2026Traditional
K261004Codman® Distal Peritoneal Catheter, Barium Open End (82-1682); Codman® HOLTER® Peritoneal Catheter (SALMON Design) (82-1684)Integra Lifesciences Production CorporationJun 23, 2026Traditional
K251598IntellidropBrainspace, Inc.Dec 10, 2025Traditional
K250636Sophy Mini Monopressure Valve (SM1)SophysaNov 28, 2025Traditional
K252514EVAC-MRIPhasor Health, LLCNov 5, 2025Traditional
K243531Codman Libertís Shunt Catheter with Bactiseal and Endexo TechnologyIntegra Lifesciences Production CorporationAug 8, 2025Traditional
K243552Codman Libertís™ 1.5 mm EVD Catheter with Bactiseal® and Endexo® Technology with Luer Connection (821761); Codman Libertís™ 1.9 mm EVD Catheter with Bactiseal® and Endexo® Technology with Luer Connection (821762)Integra Lifesciences Production CorporationAug 6, 2025Traditional
K242974External CSF Drainage Ventricular Catheters, External CSF Drainage Lumbar CathetersSophysaJun 20, 2025Traditional
K243205EVACPhasor Health, LLCJun 3, 2025Traditional
K243676Duet External Drainage and Monitoring System (EDMS)Medtronic NeurosurgeryMar 10, 2025Traditional
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 260 with a free account)

Clearances by year

67 JXG 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)2179
20258255
2024390
20235134
20224101
2021127
2020231
20194101
20186102
2017790
20166143
20156276
20133108
2012378
20117136

Who submits

24 applicants cleared a JXG device since 2011. 90% of the clearances went to applicants in United States, then France (4%), Switzerland (3%) and China (1%). By type: Traditional 82% and Special 18%.

ApplicantClearances since 2011
Aesculap, Inc.9
Codman & Shurtleff, Inc.7
Integra Lifesciences Production Corporation7
Integra LifeSciences Corporation6
Medtronic Neurosurgery6
Aqueduct Critical Care, Inc.4
Medos International SARL4
Sophysa3

How FDA classifies it

Class II (performance standards).

From 21 CFR 882.5550.

Standards

21 CFR 882.5550 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent JXG clearances declared.

Ask about JXG

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about JXG

What is FDA product code JXG?

Product code JXG, “Shunt, Central Nervous System And Components” in FDA's classification database, is a Class II device type under 21 CFR 882.5550 (central nervous system fluid shunt and components), reviewed by FDA's Neurology panel. FDA's 510(k) database lists 260 clearances under JXG, 67 of them since 2011.

How many 510(k) clearances are there under JXG?

FDA’s 510(k) database listed 260 clearances under JXG as of Oct 29, 2026, 67 of them decided since 2011; the most recent decision was Oct 2, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a JXG 510(k)?

For the 11 JXG clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 245 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most JXG clearances?

Since 2011: Aesculap, Inc. (9), Codman & Shurtleff, Inc. (7), Integra Lifesciences Production Corporation (7), Integra LifeSciences Corporation (6) and Medtronic Neurosurgery (6). 24 applicants have cleared a JXG device in that time.

Sources

  1. FDA product classification: JXG · Product Classification database
  2. 21 CFR 882.5550: Central nervous system fluid shunt and components · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for JXG · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow JXGGet an email when FDA clears, recalls or publishes guidance for JXG devices.

Know what FDA already cleared.